- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06138106
Developing a Nutritional Supplement to Increase Collagen Synthesis in People
January 28, 2026 updated by: University of California, Davis
The purpose of this study is to test whether a natural product supplement can potentiate the increase in collagen synthesis following the ingestion of collagen protein.
The investigators have developed a model of natural (GRAS certified) products that stimulate collagen synthesis, in vitro.
The investigators will determine whether the natural product supplement can potentiate the collagen synthetic response to the ingestion of collagen protein.
Basal and fed serum will be isolated and these samples will be used to treat human engineered ligaments.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kevin Paulussen, PhD
- Phone Number: 2177214479
- Email: kpaulussen@ucdavis.edu
Study Contact Backup
- Name: Keith Baar, PhD
Study Locations
-
-
California
-
Davis, California, United States, 95616
- Recruiting
- Hickey Laboratory
-
Contact:
- Keith Baar, PhD
- Email: kbaar@ucdavis.edu
-
Contact:
- Kevin Paulussen, PhD
- Email: kpaulussen@ucdavis.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Young healthy adults (18-30 y)
Exclusion Criteria:
- Pregnancy
- Smoking
- Receiving any medication that may interfere with the study outcomes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Natural Product Supplement
The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg), epicatechin (75 mg), vitamin E (350 iU) and stevia extract (225 mg).
|
Participants will have blood drawn before and one hour after consuming the natural product supplement.
For 7-days the participants will perform load-bearing exercise and consume the supplement.
On the final day, blood will be collected 4 hours after the final exercise bout.
|
|
Placebo Comparator: Placebo
The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg) and sweetener.
|
Participants will have blood drawn before and one hour after consuming the placebo supplement.
For 7-days the participants will perform load-bearing exercise and consume the supplement.
On the final day, blood will be collected 4 hours after the final exercise bout.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collagen protein synthesis
Time Frame: 7 days
|
Collagen protein synthesis will be indirectly measured by measuring pro-collagen type I N-terminal propeptide (PINP) in the serum before and 4 hours after the last exercise bout (at day 7 of the protocol).
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Strength of ligament constructs
Time Frame: 60 minutes post-exercise
|
Serum from participants will be used to treat engineered ligaments in order to measure the effect of the supplementation on the strength of the ligaments.
The strength will be measured using the Instron bio puls 68SC-1 tension and compression machine.
|
60 minutes post-exercise
|
|
Collagen content of ligament constructs
Time Frame: 60 minutes post-exercise
|
Ligament constructs will be treated for 7 days with experimental feed medium containing serum obtained at baseline or post-prandial for determination of collagen content using a hydroxyproline assay.
|
60 minutes post-exercise
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Keith Baar, PhD, University of California, Davis
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2023
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
November 3, 2023
First Submitted That Met QC Criteria
November 13, 2023
First Posted (Actual)
November 18, 2023
Study Record Updates
Last Update Posted (Actual)
January 30, 2026
Last Update Submitted That Met QC Criteria
January 28, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2110494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise
-
Centre Hospitalier de CorbieRecruitingExercise Training | Cardiac Rehabilitation | Exercise Intolerance | Exercise Intervention | Exercise Adaptations | HFrEF - Heart Failure With Reduced Ejection FractionFrance
-
Bitlis Eren UniversityCompletedExercise Physiology | Exercise ImmunologyTurkey (Türkiye)
-
Lindenwood UniversityIncrenovo, LLCRecruitingCognitive Function | Blood Flow | Nitric Oxide | Endurance Exercise | Exercise Performance | Exercise RecoveryUnited States
-
Hamza KucukCompletedExercise Training | Exercise PhysiologyTurkey (Türkiye)
-
Faculdade de Motricidade HumanaCompletedGreen Exercise | Indoor ExercisePortugal
-
Egas Moniz - Cooperativa de Ensino Superior, CRLCompletedAgeing | Aerobic Exercise | Resistance Exercise | Combined ExercisePortugal
-
Universidad Rey Juan CarlosCompletedEndurance Exercise | Running Performance | Exercise PhysiologySpain
-
Istanbul Sabahattin Zaim UniversityT.C. Dumlupınar ÜniversitesiCompletedExercise Ergogenics | Recovery Methods | Carnitine Ingestion | Exercise Fatigue | Exercise and RecoveryTurkey (Türkiye)
-
Hasan Kalyoncu UniversityNot yet recruiting
-
University of HawaiiKlein Buendel, Inc.CompletedMomZing Exercise Videos Online | Standard Exercise DVDUnited States
Clinical Trials on Natural Product Supplement
-
Capital Health, CanadaSunnybrook Health Sciences Centre; Erasmus Medical Center; IWK Health Centre; Afexa... and other collaboratorsCompletedRespiratory Tract InfectionCanada, Netherlands
-
Delivra, Inc.Completed
-
Atlantia Food Clinical TrialsCompleted
-
Federal University of ParaíbaUnknownGingivitis | Plaque AccumulationBrazil
-
Radicle ScienceActive, not recruitingPain InterferenceUnited States
-
Varol TUNALIIstanbul Medipol University Hospital; Liv Hospital (Ulus)CompletedDry Eye | Dry Eye Disease (DED) | Meibomian Gland Dysfunction (Disorder) | Dry Eye Disease, Meibomian Gland DiseaseTurkey (Türkiye)
-
Massachusetts General HospitalRecruitingMild Cognitive Impairment (MCI) | Alzheimer Disease | Subjective Cognitive Decline (SCD)United States
-
ARH van ZantenRousselot BVBA; Intensive Care Research Foundation, Gelderse Vallei HospitalTerminatedCritical Illness | Intensive Care Unit Acquired WeaknessNetherlands
-
Amazentis SASGS proderm GmbHCompleted
-
CV TechnologiesCapital Health, CanadaCompletedUpper Respiratory InfectionCanada